FBLD 2012 Agenda
(Detailed Agenda Below)
Fragment-based methods are demonstrating success in both drug
discovery and in identifying tools for chemical biology. The 2012
meeting is structured to reflect the discovery pipeline;
presentations from different specialties will be grouped together to
highlight the interplay between different scientific areas to drive
the fragment-to-optimised compound process.
- Sunday - Arrival, vendor workshops, opening reception
- Monday - Fragment Finding
- Tuesday - Fragment to Lead
- Wednesday - Success stories
There will be poster sessions running during the meeting - please see the Abstract Submission page
Updates to the scientific programme will be posted here as they become available.
The programme is now available as a PDF file.
FBLD 2012 Agenda
Monday - Introduction to Fragment Finding
- Rod Hubbard - Vernalis/York
Currrent Perspectives in FBLD
- Jane Withka - Pfizer Groton
Building Confidence for Chemistry by Generation of a Quality Library and a Multidisciplinary Approach
- Nino Campobasso - GlaxoSmithKline
Picking up the fragments at GlaxoSmithKline - No longer a last chance effort for lead ID
- Peter Kutchukian - Novartis
Privileged Substructures For Fragment-Based Screening
Question and Answer Session
Tea and Coffee Break, posters, and exhibitors
- Josh Salafsky - Biodesy
Second Harmonic Generation for allosteric and conformation-specific drug discovery: conformational change in real time
- Dallas Hughes - Selcia
Fragment Screening using Capillary Electrophoresis (CEfragTM): Complementing Existing Biophyisical and Structural Methods for Drug discovery
- Sten Ohlson - Linnaeus U
ยงIntroducing Weak Affinity Chromatography as a new approach for Fragment Screening
- Fredrik Rahm - Sprint Bioscience
Validating Thermal Shift Assays for Fragment Screening
Question and Answer Session
Lunch, posters, and exhibitors
- Charles Wartchow - Roche
Biosensor-based Lead Identification and Hit Confirmation in Fragment Screening Campaigns with Protein-Protein Interaction Targets
- Karin Regnstrom - Elan
Label free fragment screening using Surface Plasmon Resonance as a Tool for Fragment Finding: Analyzing difficult CNS targets for binding activity, selectivity, and non-specific interactions
- Helena Danielson - Beactica
Developing the tools for discovery of fragment-based leads for membrane bound targets
- Miles Congreve - Heptares
Fragment Based Drug Discovery for G Protein-Coupled Receptors
- Pamela Williams - Astex
Fragment identification using X-rays: the advantages of structural certainty
Question and Answer Session
Tea and Coffee Break, posters, and exhibitors
- Parag Sahasrabudhe - Pfizer Groton
Discovery of a Novel Fragment Inhibitor of Acetyl CoA Carboxyltransferase
- Brad Jordan - Amgen
Fragment Based Drug Discovery: Practical Implementation Based on 19F NMR Spectroscopy
- Gregg Siegal - ZoBio
Filling the Hole in Your Crystal(ography) with NMR
Question and Answer Session
Conference Dinner
Tuesday - Fragment to Lead
- Tom Peat - CSIRO
The many sites of HIV integrase: a fragment screening odyssey
- Darren Begley - Emerald
Multi-Target Fragment Screening & Structure Determination in the MEP Pathway
- Sarah Barelier - UCSF
Parallel Fragment-Screening and Docking against AmpC β-lactamase
- Kathryn Loving - Schrödinger
Recent Advances in Structure-Based Fragment Docking and Virtual Screening
Question and Answer Session
Tea and Coffee Break, posters, and exhibitors
- Man-ling Lee - Genentech
Fragment Screening Hit Triage: Advantages of Order Dependent Clustering Using a new Similarity Metric
- JW Feng - Genentech
ROCS Your Fragment Hits with Interactive 3D Similarity Search
- Carsten Detering - BioSolveIT
Supporting the Drug Discovery Pipeline: Fragment-Based Compound Manipulation and Accurate Scoring
- Sandor Vajda - Boston University
Computational protein mapping to drive the development of fragment hits into leads
Question and Answer Session
Lunch, posters, and exhibitors
- Lars Neumann - Proteros
Application of kinetic and thermodynamic parameters in FBLD
- James Murray - Vernalis
From the (k)off: The prospective use of the dissociation rate constant to guide Fragment 2 Leads Chemistry
- Yu Chen - U South Florida
Fragment-based inhibitor discovery against the CTX-M Class A β-lactamase
- Adam Renslo - UCSF
Reversible, Non-Electrophilic Inhibitors opf CTX-M Class A β-Lactamase: From Fragments to Cell-Active Leads
Question and Answer Session
Tea and Coffee Break, posters, and exhibitors
- Christopher Stubbs - U Cambridge
Allosteric Targeting of Polo-like Kinase 1: A Fragment-Based Approach
- Vickie Tsui - Genentech
Targetting Caspase-6 with Small Molecules
- Stephan G. Zech - Ariad
Discovery of highly potent inhibitors of Lactate Dehydrogenase A using fragment based drug design
- Chris Johnson - Astex
Fragment Based Lead Discovery for Challenging Targets: Allosteric Modulators and Antagonists of Protein-Protein Interactions
- Maurizio Pellecchia - Sanford-Burnham
NMR Guided Approaches to FBDD: From Fragment Identification to uHTS by NMR
Question and Answer Session
Poster session and exhibitors with refreshments
Wednesday - Success Stories
- Anders Friberg - Vanderbilt
Cancer Drug Discovery Using Fragment-Based Methods
- Andrew Petros - Abbott
Attacking Apoptosis with Fragments
- Wolfgang Jahnke - Novartis
Tuning bone affinity into fragment-derived leads
Tea and Coffee Break
- Ivan Efremov - Pfizer
Fragments vs. BACE: use of fragment-based approaches to enable a tough target
- Daniel Wyss - Merck
From Weak NMR-detected Fragment Hits to Clinical Candidates for BACE-1
- Chao Zhang - Plexxikon
Scaffolds among Fragments: Searching for Multi-faceted Progenitor of Kinase Inhibitors
Closing comments
End of conference
Last Updated: 19th September, 2012
| Tim Kirk
Back to the Top